Quick Answer
Century Therapeutics, Inc. reported Net Income Loss of -$9.58 million for the year ending 2025.
- Century Therapeutics, Inc. showed an increase of +92.4% in Net Income Loss from 2024 to 2025.
- This data is from Century Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$9.67 million | Q2 2020: -$15.30 million | Q3 2020: -$13.07 million | Q1 2021: -$18.35 million | Q2 2021: -$23.27 million | Q3 2021: -$26.01 million | Q1 2022: -$37.51 million | Q2 2022: -$30.99 million | Q3 2022: -$30.75 million | Q1 2023: -$31.26 million | Q2 2023: -$33.29 million | Q3 2023: -$32.72 million | Q1 2024: -$28.06 million | Q2 2024: -$31.21 million | Q3 2024: -$31.23 million | Q1 2025: $76.56 million | Q2 2025: -$32.54 million | Q3 2025: -$34.42 million.
- Over the full 6 years of available data (2020 to 2025), Century Therapeutics, Inc.'s Net Income Loss has grown by 82.1%.
- Historical annual values: Fiscal year 2025: -$9.58 million | Fiscal year 2024: -$126.57 million | Fiscal year 2023: -$136.67 million | Fiscal year 2022: -$130.93 million | Fiscal year 2021: -$95.82 million | Fiscal year 2020: -$53.58 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: